Drugs / 211At-OKT10-B10
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04466475 | Jan 2024 → Oct 2025 | plasma cell myeloma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 211At-OKT10-B10 | “A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous...” NCT04466475 ↗ |
| Known as | OKT10-B10 | “The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive substance called 211At.” NCT04466475 ↗ |
| Action | Deplete | “OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers 211At to kill them.” NCT04466475 ↗ |
| Modality | Monoclonal antibody | “The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody” NCT04466475 ↗ |
| Route | Intravenous | “Given IV” NCT04466475 ↗ |